E2F1 and prostate cancer: ,38 These findings, supported by both previous studies and our data from clinical cohorts and in vitro experiments, suggest that dysregulation of the RB1/E2F1 axis in advanced prostate cancer may drive lethal disease progression by regulating CDRs.